This study indicated that plasma trimethylamine N-oxide (TMAO) is a key metabolite associated with the AKI-to-CKD transition and that NADPH oxidase 2 (NOX2) activation is a key regulator of the TMAO-related AKI-to-CKD transition. This evidence concerns the gene CYBB and chronic kidney disease.